Gel-One® Cross-linked Hyaluronate is a 100% cross-linked gel, allowing for better cushioning and greater product durability1 in a single 3mL injection, giving healthcare providers confidence in addressing mild to moderate OA of the knee with a safe, effective and complete treatment.


  • Knee Injection


  • Early Intervention


  • Knee

Effective Pain Relief: 100% cross-linked, high molecular weight gel, offering increased product durability, cushioning and resistance to diffusion1

  • Demonstrated greater viscoelasticity than Synvisc/Synvisc-One®, Monovisc® and non-crosslinked HA, leading to better shock absorption and product durability1
  • Proven 91-day joint residency time1
  • Proven 26 weeks of pain relief2

Easy-to-Use: Single injection with only 3mL treatment volume

  • Patient-friendly treatment requiring only one visit for effective pain relief
  • Provides a joint-friendly treatment requiring only 3mL for effective treatment3 and chondroprotection4

Proven Safety Profile: Safe for repeat use with no increased risk of side effects2,3,5,6

  • No known reported incidences of pseudosepsis, a rare, but serious potential side effect of some viscosupplements3
  • Proven through clinical trials to be as safe as saline3



Gel-One® Cross-linked Hyaluronate

Watch animation


Indications For Use

Gel-One Hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to non-pharmacologic therapy, non-steroidal anti-inflammatory drugs (NSAIDs) or simple analgesics, e.g., acetaminophen.

Important Safety Information

Before using Gel-One Hyaluronate, ask your patients if they are allergic to hyaluronan products, cinnamon, or products from birds such as feathers, eggs, and poultry. Gel-One Hyaluronate is only for injection into the knee, performed by a doctor or other qualified health care professional. Gel-One Hyaluronate injection should not be used in the presence of a skin disease or infection around the area where the injection will be given. Gel-One Hyaluronate has not been tested to show pain relief in joints other than the knee and for conditions other than OA. Gel-One Hyaluronate has not been tested in patients who are pregnant, mothers who are nursing, or anyone under the age of 21. Strenuous or prolonged weight-bearing activities after treatment are not recommended. The effectiveness of repeat treatment cycles of Gel-One Hyaluronate has not been established. The side effects most commonly seen after injection of Gel-One Hyaluronate in the clinical trial were knee pain, swelling, and/or knee effusion.

These reactions are generally mild and do not last long. For complete instructions for use, see the package insert.

This material is intended for US Health Care Professionals.

Gel-One is a registered trademark of Seikagaku Corporation.


Additional Information

Patient Resources